Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 14 of 14 results for acalabrutinib

  1. Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)

    Evidence-based recommendations on acalabrutinib (Calquence) for treating chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    21 April 2021
    View recommendations

    Sections for TA689

  2. Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]

    Awaiting development Reference number: GID-TA11087 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]

    In development Reference number: GID-TA11230 Expected publication date:  22 April 2026

    Technology appraisal guidance
    In development

  4. Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]

    In development Reference number: GID-TA11091 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)

    Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    22 November 2023
    View recommendations

    Sections for TA931

  6. Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)

    Evidence-based recommendations on ibrutinib (Imbruvica) with venetoclax (Venclyxto) for untreated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    31 May 2023
    View recommendations

    Sections for TA891

  7. Guidance and quality standards awaiting development

    Find out which guidance and quality standards are awaiting development

  8. Guidance, NICE advice and quality standards in development

    View a complete list of all our guidance, NICE advice and quality standards currently in development

  9. Venetoclax for treating chronic lymphocytic leukaemia (TA796)

    Evidence-based recommendations on venetoclax (Venclyxto) for chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    15 June 2022
    View recommendations

    Sections for TA796

  10. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable (MA partial review of TA663) [ID6291]

    In development Reference number: GID-TA11495 Expected publication date:  18 March 2026

    Technology appraisal guidance
    In development

  11. Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]

    In development Reference number: GID-TA11298 Expected publication date:  29 January 2026

    Technology appraisal guidance
    In development

  12. Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]

    Awaiting development Reference number: GID-TA11470 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Acalabrutinib with R-CHOP for untreated non-germinal centre B-cell diffuse large B-cell lymphoma [ID6614]

    Awaiting development Reference number: GID-TA11811 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Chemotherapy-free treatment option to be offered to patients with England's most common leukaemia

    Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.

    News
    Last updated
    19 January 2024